Hematologic MalignanciesNCT06925685
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product
An observational study of Hematologic Malignancies and Solid Tumors, run by Allogene Therapeutics at 1 site in United States.
Trial summary
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Hematologic Malignancies, Solid Tumors
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jan 2025to Jan 2039
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Participants who have received an allogeneic CAR T-cell product.
Who may be able to join
- Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study
Who cannot join
- Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Long Term Follow up Study for Participants Treated With an Allogeneic CAR T-Cell Product in a Prior Clinical Study
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.
- Conditions
- Hematologic Malignancies, Solid Tumors
- Keywords
- CAR T, Allogeneic CAR T, long term follow up
- Medical subject headings
- Hematologic Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs
Measured: Up to 15 years post treatment with allogeneic CAR T-cell product
Overall survival (OS)
Measured: Up to 15 years post treatment with allogeneic CAR T cell product
Presence of replication competent lentivirus (RCL) in blood
Measured: Up to 15 years post treatment with allogeneic CAR T cell product
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2025
- Study start31 Jan 2025
- Primary completionJan 2039 (estimated)
- Study completionJan 2039 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematologic MalignanciesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Allogene Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Allogene Study Director, Study director, Allogene Therapeutics, Inc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06925685
- Sponsor's protocol ID
- ALLO-LTFU-101
- Status last verified
- Oct 2026
- First submitted
- 7 Apr 2025
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No